197 related articles for article (PubMed ID: 19262468)
21. Placebo surgery research: a blinding imperative.
Heckerling PS
J Clin Epidemiol; 2006 Sep; 59(9):876-80. PubMed ID: 16895807
[TBL] [Abstract][Full Text] [Related]
22. Epidemiological study designs.
Diomidus M
Stud Health Technol Inform; 2002; 65():126-35. PubMed ID: 15460223
[TBL] [Abstract][Full Text] [Related]
23. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
[TBL] [Abstract][Full Text] [Related]
24. Can open-label studies demonstrate efficacy in improving sexual function?
Michel MC; Meissner A
Int J Impot Res; 2009; 21(4):265; author reply 265-6. PubMed ID: 19603043
[No Abstract] [Full Text] [Related]
25. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
26. Corporate influence over planning and presentation of clinical trials: beauty and the beast.
Fuchs FD
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):7-9. PubMed ID: 20014930
[No Abstract] [Full Text] [Related]
27. Cost-effectiveness of different study designs: an overlooked parameter in clinical research.
Falagas ME; Bliziotis IA
J Clin Epidemiol; 2007 Mar; 60(3):215-6. PubMed ID: 17292014
[No Abstract] [Full Text] [Related]
28. Multi-arm clinical trials of new agents: some design considerations.
Freidlin B; Korn EL; Gray R; Martin A
Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study.
Pratt CM; Reiffel JA; Ellenbogen KA; Naccarelli GV; Kowey PR
Am Heart J; 2009 Aug; 158(2):163-169.e1-3. PubMed ID: 19619690
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
[TBL] [Abstract][Full Text] [Related]
31. Interpreting clinical trials: the 'beautiful' case.
Agewall S; Atar D
Fundam Clin Pharmacol; 2009 Apr; 23(2):261-2. PubMed ID: 19236485
[No Abstract] [Full Text] [Related]
32. End points for cardiovascular drug trials in pediatric patients.
Sinaiko AR; Lauer RM; Sanders SP
Am Heart J; 2001 Aug; 142(2):229-32. PubMed ID: 11479459
[No Abstract] [Full Text] [Related]
33. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
34. [Placebo surgery for clinical studies?].
Neye H
Med Monatsschr Pharm; 1999 Oct; 22(10):317-9. PubMed ID: 10540804
[No Abstract] [Full Text] [Related]
35. Cohort profile: design and methods of the PREDIMED study.
Martínez-González MÁ; Corella D; Salas-Salvadó J; Ros E; Covas MI; Fiol M; Wärnberg J; Arós F; Ruíz-Gutiérrez V; Lamuela-Raventós RM; Lapetra J; Muñoz MÁ; Martínez JA; Sáez G; Serra-Majem L; Pintó X; Mitjavila MT; Tur JA; Portillo MP; Estruch R;
Int J Epidemiol; 2012 Apr; 41(2):377-85. PubMed ID: 21172932
[No Abstract] [Full Text] [Related]
36. 'Liberal' vs. 'restrictive' perioperative fluid therapy--a critical assessment of the evidence.
Bundgaard-Nielsen M; Secher NH; Kehlet H
Acta Anaesthesiol Scand; 2009 Aug; 53(7):843-51. PubMed ID: 19519723
[TBL] [Abstract][Full Text] [Related]
37. [Physical activity and prevention of Alzheimer's dementia: current evidence and feasibility of an interventional trial].
Weih M; Abu-Omar K; Esselmann H; Gelbrich G; Lewczuk P; Rütten A; Wiltfang J; Kornhuber J
Fortschr Neurol Psychiatr; 2009 Mar; 77(3):146-51. PubMed ID: 19283649
[TBL] [Abstract][Full Text] [Related]
38. ETC-588 (Pfizer).
Doggrell SA
Curr Opin Investig Drugs; 2004 Sep; 5(9):993-9. PubMed ID: 15503656
[TBL] [Abstract][Full Text] [Related]
39. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
[TBL] [Abstract][Full Text] [Related]
40. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
